tiprankstipranks
DiaSorin completes sale of Flow Cytometry & Imaging business to Cytek
The Fly

DiaSorin completes sale of Flow Cytometry & Imaging business to Cytek

DiaSorin (DSRLF) and Cytek Biosciences, Inc. (CTKB) announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging business unit to Cytek for approximately $46.5M. The decision to sell the FCI business unit to Cytek, announced on February 13, 2023, is in line with DiaSorin’s strategic priorities communicated to investors during the Capital Market Day in December 2021 to focus on the core for its future. The acquisition supports Cytek’s plan to develop new products and capabilities with FCI technology, expand its reach and offerings into customer segments previously underserved, and increase the efficiency of its operations.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CTKB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles